Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
Authors
Keywords
-
Journal
Cancer Medicine
Volume 10, Issue 21, Pages 7665-7672
Publisher
Wiley
Online
2021-10-01
DOI
10.1002/cam4.4295
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
- (2020) B. Porte et al. BREAST
- Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy
- (2019) Leticia Varella et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy
- (2019) Maria Teresa Masucci et al. Frontiers in Oncology
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3
- (2018) Massimo Cristofanilli et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients
- (2015) Mirco Pistelli et al. BMC CANCER
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
- (2015) Seth B. Coffelt et al. NATURE
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- How Neutrophils Shape Adaptive Immune Responses
- (2015) Pieter H. C. Leliefeld et al. Frontiers in Immunology
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting
- (2014) Young Wha Koh et al. TUMOR BIOLOGY
- Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences
- (2013) Janesh Pillay et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients
- (2013) Hany Noh et al. Journal of Breast Cancer
- Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients
- (2013) Basem Azab et al. MEDICAL ONCOLOGY
- Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
- (2012) Claudia A. Dumitru et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients
- (2011) Basem Azab et al. ANNALS OF SURGICAL ONCOLOGY
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Neutrophils: key mediators of tumour angiogenesis
- (2010) Simon Tazzyman et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model
- (2010) Jadwiga Jablonska et al. JOURNAL OF CLINICAL INVESTIGATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started